Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation

Author(s): Sara Mongiorgi, Matilde Y. Follo, Yong Ryoul Yang, Stefano Ratti, Lucia Manzoli, James A. McCubrey, Anna Maria Billi, Pann-Ghill Suh, Lucio Cocco

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 16 , 2016

Become EABM
Become Reviewer

Abstract:

Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).

Keywords: PI-PLCbeta1, Nucleus, Cell Cycle, Differentiation, Hematopoiesis, MDS.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 16
Year: 2016
Page: [2345 - 2348]
Pages: 4
DOI: 10.2174/1381612822666160226132338
Price: $65

Article Metrics

PDF: 25
HTML: 4
PRC: 2